NRAS destines tumor cells to the lungs

NRAS destines tumor cells to the lungs

The lungs are frequently affected by cancer metastasis. Although NRAS mutations have been associated with metastatic potential, their exact role in lung homing is incompletely understood. We cross-examined the genotype of various tumor cells with their ability for automatic pulmonary dissemination,...

Bibliografiset tiedot
Päätekijät:	Giannou, AD, Marazioti, A, Kanellakis, NI, Giopanou, I, Lilis, I, Zazara, DE, Ntaliarda, G, Kati, D, Armenis, V, Giotopoulou, GA, Krontira, AC, Lianou, M, Agalioti, T, Vreka, M, Papageorgopoulou, M, Fouzas, S, Kardamakis, D, Psallidas, I, Spella, M, Stathopoulos, GT
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	EMBO Press 2017

Samankaltaisia teoksia

NRAS destines tumor cells to the lungs
Tekijä: Anastasios D Giannou, et al.
Julkaistu: (2017-03-01)

IκB Kinase α is required for development and progression of KRAS-mutant lung adenocarcinoma
Tekijä: Vreka, M, et al.
Julkaistu: (2018)

LSC Abstract – Host-environmental IL-1b drives mutant KRAS-IKKa addiction in malignant pleural effusion
Tekijä: Marazioti, A, et al.
Julkaistu: (2016)

S7 Mouse lung adenocarcinoma cell lines reveal PRL2C2 as a novel lung tumour promoter
Tekijä: Kanellakis, N, et al.
Julkaistu: (2016)

Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion
Tekijä: Marazioti, A, et al.
Julkaistu: (2018)

LSC-2017-Mouse lung adenocarcinoma cell lines as tools to identify novel lung cancer genes
Tekijä: Kanellakis, N, et al.
Julkaistu: (2017)

Tumor-derived osteopontin isoforms cooperate with TRP53 and CCL2 to promote lung metastasis
Tekijä: Giopanou, I, et al.
Julkaistu: (2016)

Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion
Tekijä: Antonia Marazioti, et al.
Julkaistu: (2018-02-01)

LSC - 2017 - CREB signaling in KRAS-driven lung adenocarcinoma
Tekijä: Giotopoulou, G, et al.
Julkaistu: (2017)

S8 Osteopontin as an airway epithelial tumour promoter
Tekijä: Psallidas, I, et al.
Julkaistu: (2016)

Club cells form lung adenocarcinomas and maintain the alveoli of adult mice
Tekijä: Spella, M, et al.
Julkaistu: (2019)

cAMP-response element binding protein in KRAS-driven lung adenocarcinoma
Tekijä: Giotopoulou, G, et al.
Julkaistu: (2016)

LSC Abstract – Osteopontin as an airway epithelial tumor promoter
Tekijä: Psallidas, I, et al.
Julkaistu: (2016)

Comprehensive Evaluation of Nuclear Factor-κΒ Expression Patterns in Non-Small Cell Lung Cancer.
Tekijä: Ioanna Giopanou, et al.
Julkaistu: (2015-01-01)

Tumor cell-derived osteopontin promotes lung metastasis via both cell-autonomous and paracrine pathways
Tekijä: Kanellakis, N, et al.
Julkaistu: (2016)

Mutant KRAS promotes malignant pleural effusion formation
Tekijä: Theodora Agalioti, et al.
Julkaistu: (2017-05-01)

Interleukin-1β provided by KIT-competent mast cells is required for KRAS-mutant lung adenocarcinoma
Tekijä: Ioannis Lilis, et al.
Julkaistu: (2019-07-01)

Mutant KRAS promotes malignant pleural effusion formation
Tekijä: Αgalioti, T, et al.
Julkaistu: (2017)

Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion.
Tekijä: Antonia Marazioti, et al.
Julkaistu: (2013-01-01)

Club cells form lung adenocarcinomas and maintain the alveoli of adult mice
Tekijä: Magda Spella, et al.
Julkaistu: (2019-05-01)

RAS oncogenes direct metastasis
Tekijä: Magda Spella, et al.
Julkaistu: (2017-09-01)

Shared epithelial pathways to lung repair and disease
Tekijä: Magda Spella, et al.
Julkaistu: (2017-06-01)

Clinical identification of malignant pleural effusions
Tekijä: Jianlong Jia, et al.
Julkaistu: (2024-01-01)

KRAS signaling in malignant pleural mesothelioma
Tekijä: Antonia Marazioti, et al.
Julkaistu: (2021-12-01)

An In Vivo Inflammatory Loop Potentiates KRAS Blockade
Tekijä: Kristina A. M. Arendt, et al.
Julkaistu: (2022-03-01)

Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight
Tekijä: Anne-Sophie Lamort, et al.
Julkaistu: (2019-08-01)

NRAS mutation in differentiated thyroid cancer
Tekijä: Saswata Saha, et al.
Julkaistu: (2022-01-01)

NRAS and BRAF mutation frequency in primary oral mucosal melanoma
Tekijä: Buery, R.R., et al.
Julkaistu: (2011)

Targeted therapies for lung cancer: how did the game begin?
Tekijä: Kanellakis, N, et al.
Julkaistu: (2016)

Deregulated Nras expression in knock-in animals harboring a gammaretroviral long terminal repeat at the Nras/Csde1 locus.
Tekijä: Borja Ballarín-González, et al.
Julkaistu: (2013-01-01)

Inherited genetic variants associated with melanoma BRAF/NRAS subtypes
Tekijä: Thomas, NE, et al.
Julkaistu: (2018)

MEK inhibitors for the treatment of NRAS mutant melanoma
Tekijä: Sarkisian S, et al.
Julkaistu: (2018-08-01)

KRAS and NRAS genes mutations as biomarkers in the therapy of colorectal cancer and the basic methods of their detection
Tekijä: Olga I. Brovkina, et al.
Julkaistu: (2021-03-01)

Computational Analysis of Deleterious SNPs in NRAS to Assess Their Potential Correlation With Carcinogenesis
Tekijä: Mohammed Y. Behairy, et al.
Julkaistu: (2022-08-01)

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.
Tekijä: Michael K Kiessling, et al.
Julkaistu: (2016-01-01)

Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation
Tekijä: Brandon M. Murphy, et al.
Julkaistu: (2022-06-01)

Novel mouse model of indwelling pleural catheter in mice with malignant pleural effusion
Tekijä: Merrick, C, et al.
Julkaistu: (2019)

Impact of NRAS Mutations on the Diagnosis of Follicular Neoplasm of the Thyroid
Tekijä: Ja-Seong Bae, et al.
Julkaistu: (2014-01-01)

Advances in the treatment of advanced melanoma with NRAS gene mutation
Tekijä: ZHAO Bolun, ZHU Guannan
Julkaistu: (2023-10-01)

Acquisition of loss of the wild-type NRAS locus with aggressive disease progression in a patient with juvenile myelomonocytic leukemia and a heterozygous NRAS mutation
Tekijä: Kazuyuki Matsuda, et al.
Julkaistu: (2007-11-01)